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Molecular types of breast cancer
Important differences in the clinical behaviour of oestrogen
receptor (ER)-positive and ER-negative cancers have been
recognised for a long time [1]. Nevertheless, breast cancer
was regarded as a single disease with variable histology and
clinical course. More recently, high-throughput analytical
methods revealed unexpectedly large-scale molecular differ-
ences between ER-positive cancers and ER-negative cancers
[2]. These results prompted a conceptual shift in the classifi-
cation of breast cancer, which is increasingly viewed not as a
single disease but as a collection of several biologically distinct
neoplastic diseases that arise from the breast epithelium.
The different molecular types of breast cancer may originate
from different epithelial precursors such as luminal (ER-
positive cancers) or basal (ER-negative tumours) epithelial
cells, or may represent different stages of arrest along a
spectrum of differentiation [3,4]. ER-positive cancers can be
further divided into good prognosis and poor prognosis
subgroups. At the molecular level, this division corresponds
to differences in proliferative activity [5]. Clinical hetero-
geneity also exists within ER-negative cancers but the
molecular differences that are associated with prognosis or
chemotherapy sensitivity are less easily identifiable with gene
expression analysis or other high-throughput analytical
methods. This may be due to fewer and more subtle
molecular differences between subsets of ER-negative
cancers or to a larger number of subsets that exist among
these tumours, and therefore their delineation will require
much larger sample sizes than currently available.
Four different molecular types of breast cancers can currently
be defined with confidence: ER/progesterone receptor-
negative and HER-2-negative (triple-negative or basal-like)
breast cancer; highly proliferative ER-positive breast cancer
(luminal B type or MammaPrint high risk or OncotypeDX high
recurrence score cancers); low proliferation ER-positive
breast cancers (luminal A type or MammaPrint low risk or
OncotypeDX low recurrence score cancers); and HER-2
amplified breast cancer. The gene expression characteristics
that define the HER-2 amplified cancers are smaller than
those that define triple-negative breast cancers or separate
the low-risk and high-risk ER-positive cancers, but consider-
ing HER-2-positive cancers as a separate molecular type is
nevertheless justified on the grounds of its unique sensitivity
to HER-2 targeted therapies and the characteristic HER2
gene amplification that defines this disease.
It is important to recognise that there is no standardised and
uniformly accepted molecular assay to assign molecular class
to breast cancer. The original intrinsic subtype predictor has
undergone important methodological changes in each
subsequent publication. The genes that are used for
classification, the prediction algorithm, and the reference or
training population vary from manuscript to manuscript.
Clinicians adopted a simple, routine marker-based classifi-
cation schema that includes triple-negative cancers, HER-2
amplified cancers and low-proliferation and high proliferation
ER-positive cancers. These four clinical subsets correspond
closely (≥80% concordance) to groups defined by various
molecular classification methods that rely on gene expression
analysis or immunohistochemistry. The schema attests for the
robustness of the original concept that all the different
molecular classification methods tend to assign individual
patients, with reasonably high concordance, to the same
molecular subtype.
Which ER-positive breast cancers require
adjuvant chemotherapy in addition to
endocrine treatment?
This question represents a central challenge in the manage-
ment of stage I to stage II ER-positive breast cancers, and the
answer often relies on a great deal of clinical judgment.
Chemotherapy selection for these patients is largely based
on the estimated risk of recurrence determined by tumour
size and nodal status. Seasoned clinicians also consider the
age of the patient, tumour grade and perhaps the semi-
quantitative ER, progesterone receptor and Ki67 expression
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values that each influence to a variable extent the risk of
recurrence and endocrine sensitivity. Unfortunately, the
human mind is not well suited for rapid and reproducible
calculation of multivariate prediction models. It is difficult to
estimate precisely whether a 47-year-old woman with a 1.8
cm, grade 2, 15% ER-positive, 10% Ki67 invasive cancer has
better or worse prognosis than a 65-year-old woman with a 3
cm, 80% ER-positive and high nuclear grade tumour.
The most important practical implication of gene expression
analysis and the new molecular classification schema of
breast cancer has been the development of multigene-
prognostic predictors that can assist in assessing the risk of
recurrence in ER-positive cancers. Multigene predictors are
conceptually similar to other multivariate outcome prediction
models such as the AdjuvantOnline prognostic model or
nomograms that predict complete response to neoadjuvant
chemotherapy or the probability of finding additional positive
axillary lymph nodes after a positive sentinel lymph node
biopsy [6-8]. The multivariate models have two important
advantages over the gestalt of physicians; they combine
variables in a mathematically optimal manner by weighing the
importance of each variable based on evidence (derived from
the training data), and they provide a standardised tool for
decision-making.
Owing to the substantial molecular differences that exist
between poor prognosis and good prognosis ER-positive
cancers that are driven by the large number of genes involved
in regulating and executing cell proliferation, it is relatively
easy to develop gene expression-based prognostic predic-
tors for ER-positive cancers. Indeed, a number of such
markers have been proposed and newer ones are constantly
reported. Not all of these, however, are equally ready for
clinical use. Reproducibility and robustness of the analytical
method must be established along with potential sources of
variation. The assay procedure has to be standardised and
the decision thresholds have to be fully defined before clinical
validation. The predictive performance of the proposed assay
needs to be validated in independent patient cohorts that
meet the characteristics of the intended use of the assay (for
example, a prognostic assay cannot be meaningfully tested
on patients who receive different types of systemic adjuvant
therapies). The validation sample size has to be large enough
to yield sufficiently narrow confidence intervals around the
point estimates of test performance.
The generation of such supporting data is expensive, time
consuming and it is often painstakingly difficult to obtain the
appropriate clinical samples. Not surprisingly, therefore, few
tests have gone through these validation steps. The best
evidence currently exists for the use of the OncotypeDX
assay as a risk stratification tool for ER-positive breast
cancer. There are also convincing data to support the use of
MammaPrint for a similar purpose. The performance charac-
teristics and the data that support their use have extensively
been reviewed in several recent manuscripts [2,9]. It is
important to recognise that OncotypeDX is not helpful to
predict prognosis of ER-negative patients because all of
these patients are categorised as high risk for recurrence.
Similarly, MammaPrint is also not very efficient in identifying
good prognosis ER-negative cancers – it categorises almost
all ER-negative cancers (>90%) as high risk. It is certain that
new assays will enter the market shortly with similar function
(for example, the genomic grade index, PAM50) [10,11].
An important and consistently observed phenomenon in
genomic prognostic marker research is that these predictors
provide independent prognostic information when considered
together with routine clinical characteristics (for example,
tumour size, nodal status, histological grade) in multivariate
analysis [2,9]. Equally importantly, however, the tumour size
and nodal status also provide prognostic information
independent of the genomic assay results. This suggests that
integration of molecular predictor results with tumour size and
nodal status could further increase predictive accuracy and
should be considered together in the decision-making
process. It is clear in several clinical scenarios that appro-
priate decisions can be made without the use of any
molecular prognostic test; in many circumstances, however,
these tests can lead to more informed decision-making.
One study for all breast cancers or separate
studies for each molecular subtype?
If breast cancer is a collection of several distinct neoplastic
diseases, than it may not be prudent to conduct a single
therapeutic trial or prognostic marker discovery study for all
breast cancers together. Indeed, some of the conflicting
results from various randomised therapeutic trials and
biomarker studies may be explained by the unrecognised
molecular heterogeneity and unintended systematic differ-
ences in trial populations. For example, different adjuvant
clinical trials can accrue substantially different proportions of
OncotypeDX low-risk and high-risk ER-positive cancers [12].
These differences can have a profound effect on the power of
these studies to measure chemotherapy effect. A modest
increase in the proportion of low-risk patients (who benefit
little or none from adjuvant chemotherapy) from 40 to 60%
can decrease the power of a trial from 80 to 60% to detect
benefit from adjuvant chemotherapy [12].
It is also plausible to assume that different prognostic and
treatment response markers may be optimal for the different
molecular types of breast cancer. Indeed, emerging data
suggest that even traditional markers such as proliferation
carry different predictive values in ER-positive cancers and in
ER-negative cancers [5]. Proliferative activity is generally
higher in ER-negative breast cancers compared with ER-
positive disease, but its prognostic and predictive value is
less within the ER-negative subset than among ER-positive
cancers. Different thresholds can be optimal to separate
cases into low or high marker groups among ER-positive andER-negative cancers, respectively. Systematically different
distribution of the genomic grade index (a 90-gene signature
that distinguishes low-grade and high-grade cancers)
between ER-positive and ER-negative cancers was also
observed and translated into different chemotherapy
response predictive values in these two different types of
cancers [13].
A further potential confounder in combined analysis of all
breast cancers in a biomarker study is that the same bio-
marker can interact to a variable, and sometimes opposing,
extent with several different biological functions that
determine survival. For example, microtubule binding protein
Tau is an oestrogen-regulated gene that has low expression
in ER-negative cancers and in luminal B, highly proliferative,
ER-positive cancers. Combined analysis of all breast cancers
can easily identify low expression of this molecule as a marker
of increased chemotherapy sensitivity since ER-negative
cancers and highly proliferative ER-positive cancers are more
sensitive to cytotoxic drugs. Because of its association with
the molecular and clinical phenotype, however, high
expression of Tau can also be considered a marker of good
prognosis, endocrine-sensitive, ER-positive cancers [14].
When overall survival is plotted for all patients treated with
endocrine and chemotherapies by Tau status, high Tau
expression may be associated with better survival (if most
patients in the study are ER-positive and the sensitivity of
high Tau to predict endocrine responsiveness is greater than
its sensitivity to predict chemotherapy resistance) or it may be
associated with worse survival (if most patients are ER-
negative and high Tau has higher sensitivity for predicting
chemotherapy resistance than endocrine sensitivity) [15].
Similar opposing associations exist between proliferative
activity, tumour grade, OncotypeDX score, and chemo-
therapy and endocrine therapy sensitivity. Such associations
lead to apparent paradoxes such as high-grade cancers
being more sensitive to chemotherapy yet having worse
overall survival. Predictive and prognostic marker research
would benefit from refocusing efforts to develop markers
separately for different clinical and molecular types of breast
cancers.
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